Cryoport, Inc., a life sciences services company, provides temperature-controlled logistics solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoportal, a cloud-based logistics management platform that supports the management of shipments, which includes order entry, document preparation, customs documentation, courier management, real-time shipment tracking and monitoring, issue resolution, and regulatory compliance requirements; and CryoPort Express Shippers, which is used to ensure that the stability of shipped biologic commodities are maintained throughout the shipping cycle; and Cryoport Express Advanced Therapy Shippers that provides verification processes to biopharma companies. It also provides information dashboards and validation documentation for shipments through data collected by the SmartPak Condition Monitoring System; and vacuum insulated aluminum dewars and cryogenic freezers systems. In addition, the company offers biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; transportation of frozen biological specimens to and from customer locations; and management of incoming and outgoing biological specimens, as well as provides logistics support and management; and short-term logistics and engineering consulting services. It serves biopharma/pharma, animal health, and human reproductive medicine markets. The company was founded in 1999 and is headquartered in Brentwood, Tennessee.
IPO Year:
Exchange: NASDAQ
Website: cryoport.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/6/2025 | Sector Weight → Overweight | KeyBanc Capital Markets | |
| 8/6/2025 | $16.00 | Market Perform → Outperform | Leerink Partners |
| 7/22/2025 | $13.00 | Overweight | Stephens |
| 3/24/2025 | $10.00 | Neutral → Buy | UBS |
| 12/19/2024 | $11.00 | Buy | Guggenheim |
| 12/19/2024 | $11.00 | Buy | Canaccord Genuity |
| 8/7/2024 | $20.00 → $8.00 | Buy → Hold | Jefferies |
| 7/31/2024 | $19.00 → $15.00 | Neutral → Buy | B. Riley Securities |
| 5/3/2024 | $22.00 → $19.00 | Buy → Neutral | B. Riley Securities |
| 4/4/2024 | $17.00 → $21.00 | Buy | Jefferies |
Fastest customizable press release news feed in the world
Second quarter revenue increased 14% year-over-year to $45.5 millionCommercial Cell & Gene Therapy revenue increased 33% year-over-year to $8.7 millionLife Sciences Services revenue rose 21% year-over-year, including a 28% increase in BioStorage/BioServices revenue Launched strategic partnership agreement with the DHL Group; closed CRYOPDP divestitureCompany reaffirms full year 2025 revenue guidance of $165 to $172 millionNASHVILLE, Tenn., Aug. 5, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) ("Cryoport" or the "Company"), a leading global provider of temperature-controlled supply chain solutions for the life sciences, today announced financial results for its second quarter (Q2) and fir
NASHVILLE, Tenn., July 22, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences, today announced that the Company will report financial results for the second quarter ended June 30, 2025 on Tuesday, August 5, 2025 after U.S. markets close. In addition to the earnings release, a document titled "Cryoport Second Quarter 2025 in Review", providing a review of Cryoport's financial and operational performance and a general business update, will be issued at 4:05 p.m. E
New SC vapor shipper series improves reliability through extended hold times and patented impact-absorbing and Vapor Shield Technology NASHVILLE, Tenn., July 8, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX), a global leader in temperature-controlled supply chain solutions for the life sciences, today announced the launch of MVE Biological Solutions' new vapor shippers, the SC 4/2V and SC 4/3V, offering medical and animal health professionals, laboratories, researchers, hospitals and clinics, pharmaceutical companies, and others dramatically improved safety and reliability for transporting and preserving sensitive biological materials at cryogenic temperatures.
NASHVILLE, Tenn., June 12, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) ("Cryoport" or the "Company"), a leader in temperature-controlled supply chain solutions for the Life Sciences, with a focus on regenerative medicine, today announced the completion of the previously disclosed divestiture of its specialty courier business, CRYOPDP, to DHL Group ("DHL"), one of the world's leading logistics providers, in a transaction that includes cash payments of approximately $200 million to Cryoport. Concurrently, Cryoport and DHL have established a strategic partnership aimed at e
Commercial Cell & Gene therapy revenue of $7.2 million, up 33% year over yearQ1 2025 revenue from continuing operations of $41.0 million, up 10% year over yearSupporting 711 global clinical trials as of March 31, 2025Strategic partnership with DHL; CRYOPDP divestiture expected to close Q2/Q3 2025NASHVILLE, Tenn., May 7, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) (Cryoport), a global provider of temperature-controlled supply chain solutions for the life sciences sector, today announced financial results for the first quarter (Q1) ended March 31, 2025. Jerrell Shelton, C
NASHVILLE, Tenn., April 24, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) ("Cryoport" or the "Company"), a global provider of supply chain solutions for the life sciences sector, today announced that the Company will report financial results for the first quarter ended March 31, 2025 on Wednesday, May 7, 2025 after U.S. markets close. In addition to the earnings release, a document titled "Cryoport First Quarter 2025 in Review", providing a review of Cryoport's financial and operational performance and a general business update, will be issued at 4:05 p.m. ET on Wednesday,
DHL to acquire 100% of CRYOPDP, a leading specialty courier providing logistics services for clinical trials, biopharma, and cell & gene therapies. This acquisition enhances DHL's capabilities in specialty pharma logistics and supports Group's 2030 strategy to become a leader in life science and healthcare logistics.DHL and Cryoport form strategic partnership to strengthen their respective supply chain services offerings for the global life sciences and healthcare sector.BONN, Germany and NASHVILLE, Tenn., March 31, 2025 /PRNewswire/ -- DHL Group ("DHL"), the world's leading logistics provider, and Cryoport, Inc. (NASDAQ:CYRX) ("Cryoport"), a global provider of supply chain solutions for the
NASHVILLE, Tenn., March 31, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) ("Cryoport" or the "Company"), a global leader in supply chain solutions for the life sciences sector, today announced that the Company will host an investor call today, Monday, March 31, 2025, at 8:30 a.m. ET, to discuss the Company's recent strategic agreement and transformative transaction, which includes a strategic partnership with the DHL Group (DHL) and DHL's acquisition of CRYOPDP The conference call will include remarks by the management team followed by a questions and answers session that
NASHVILLE, Tenn., March 12, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) ("Cryoport" or "the Company"), a global leader in supply chain solutions for the life sciences, today announced the launch of MVE Biological Solutions' ("MVE") High-Efficiency 800 C, the latest addition to its next-generation High-Efficiency ("HE") Series of cryogenic freezers. The HE 800 C combines ergonomic features and consistent performance in a compact size to meet the evolving needs of fertility clinics, biorepositories and clinical laboratories. "With the HE 800 C, we are delivering an unmatch
FY 2024 revenue of $228.4 million, in-line with company guidanceCommercial Cell & Gene Therapy revenue rose to $26 million in FY 2024, up 20% year-over-year Supporting a record total of 701 global clinical trials as of December 31, 2024NASHVILLE, Tenn., March 4, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) (Cryoport), a global leader in supply chain solutions for the life sciences industry, today announced financial results for the fourth quarter (Q4) and year ended (FY) December 31, 2024. Jerrell Shelton, CEO of Cryoport, commented, "Cryoport ended 2024 with solid resul
SCHEDULE 13G/A - Cryoport, Inc. (0001124524) (Subject)
SCHEDULE 13G/A - Cryoport, Inc. (0001124524) (Subject)
10-Q - Cryoport, Inc. (0001124524) (Filer)
NT 10-Q - Cryoport, Inc. (0001124524) (Filer)
8-K - Cryoport, Inc. (0001124524) (Filer)
8-K - Cryoport, Inc. (0001124524) (Filer)
SD - Cryoport, Inc. (0001124524) (Filer)
SCHEDULE 13G/A - Cryoport, Inc. (0001124524) (Subject)
SCHEDULE 13G/A - Cryoport, Inc. (0001124524) (Subject)
10-Q - Cryoport, Inc. (0001124524) (Filer)
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Cryoport, Inc. (0001124524) (Issuer)
4 - Cryoport, Inc. (0001124524) (Issuer)
4 - Cryoport, Inc. (0001124524) (Issuer)
4 - Cryoport, Inc. (0001124524) (Issuer)
4 - Cryoport, Inc. (0001124524) (Issuer)
4 - Cryoport, Inc. (0001124524) (Issuer)
4 - Cryoport, Inc. (0001124524) (Issuer)
4 - Cryoport, Inc. (0001124524) (Issuer)
4 - Cryoport, Inc. (0001124524) (Issuer)
4 - Cryoport, Inc. (0001124524) (Issuer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
KeyBanc Capital Markets upgraded Cryoport from Sector Weight to Overweight
Leerink Partners upgraded Cryoport from Market Perform to Outperform and set a new price target of $16.00
Stephens resumed coverage of Cryoport with a rating of Overweight and set a new price target of $13.00
UBS upgraded Cryoport from Neutral to Buy and set a new price target of $10.00
Guggenheim initiated coverage of Cryoport with a rating of Buy and set a new price target of $11.00
Canaccord Genuity initiated coverage of Cryoport with a rating of Buy and set a new price target of $11.00
Jefferies downgraded Cryoport from Buy to Hold and set a new price target of $8.00 from $20.00 previously
B. Riley Securities upgraded Cryoport from Neutral to Buy and set a new price target of $15.00 from $19.00 previously
B. Riley Securities downgraded Cryoport from Buy to Neutral and set a new price target of $19.00 from $22.00 previously
Jefferies resumed coverage of Cryoport with a rating of Buy and set a new price target of $21.00 from $17.00 previously
Live finance-specific insights
Second quarter revenue increased 14% year-over-year to $45.5 millionCommercial Cell & Gene Therapy revenue increased 33% year-over-year to $8.7 millionLife Sciences Services revenue rose 21% year-over-year, including a 28% increase in BioStorage/BioServices revenue Launched strategic partnership agreement with the DHL Group; closed CRYOPDP divestitureCompany reaffirms full year 2025 revenue guidance of $165 to $172 millionNASHVILLE, Tenn., Aug. 5, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) ("Cryoport" or the "Company"), a leading global provider of temperature-controlled supply chain solutions for the life sciences, today announced financial results for its second quarter (Q2) and fir
NASHVILLE, Tenn., July 22, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences, today announced that the Company will report financial results for the second quarter ended June 30, 2025 on Tuesday, August 5, 2025 after U.S. markets close. In addition to the earnings release, a document titled "Cryoport Second Quarter 2025 in Review", providing a review of Cryoport's financial and operational performance and a general business update, will be issued at 4:05 p.m. E
Commercial Cell & Gene therapy revenue of $7.2 million, up 33% year over yearQ1 2025 revenue from continuing operations of $41.0 million, up 10% year over yearSupporting 711 global clinical trials as of March 31, 2025Strategic partnership with DHL; CRYOPDP divestiture expected to close Q2/Q3 2025NASHVILLE, Tenn., May 7, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) (Cryoport), a global provider of temperature-controlled supply chain solutions for the life sciences sector, today announced financial results for the first quarter (Q1) ended March 31, 2025. Jerrell Shelton, C
NASHVILLE, Tenn., April 24, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) ("Cryoport" or the "Company"), a global provider of supply chain solutions for the life sciences sector, today announced that the Company will report financial results for the first quarter ended March 31, 2025 on Wednesday, May 7, 2025 after U.S. markets close. In addition to the earnings release, a document titled "Cryoport First Quarter 2025 in Review", providing a review of Cryoport's financial and operational performance and a general business update, will be issued at 4:05 p.m. ET on Wednesday,
DHL to acquire 100% of CRYOPDP, a leading specialty courier providing logistics services for clinical trials, biopharma, and cell & gene therapies. This acquisition enhances DHL's capabilities in specialty pharma logistics and supports Group's 2030 strategy to become a leader in life science and healthcare logistics.DHL and Cryoport form strategic partnership to strengthen their respective supply chain services offerings for the global life sciences and healthcare sector.BONN, Germany and NASHVILLE, Tenn., March 31, 2025 /PRNewswire/ -- DHL Group ("DHL"), the world's leading logistics provider, and Cryoport, Inc. (NASDAQ:CYRX) ("Cryoport"), a global provider of supply chain solutions for the
NASHVILLE, Tenn., March 31, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) ("Cryoport" or the "Company"), a global leader in supply chain solutions for the life sciences sector, today announced that the Company will host an investor call today, Monday, March 31, 2025, at 8:30 a.m. ET, to discuss the Company's recent strategic agreement and transformative transaction, which includes a strategic partnership with the DHL Group (DHL) and DHL's acquisition of CRYOPDP The conference call will include remarks by the management team followed by a questions and answers session that
FY 2024 revenue of $228.4 million, in-line with company guidanceCommercial Cell & Gene Therapy revenue rose to $26 million in FY 2024, up 20% year-over-year Supporting a record total of 701 global clinical trials as of December 31, 2024NASHVILLE, Tenn., March 4, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) (Cryoport), a global leader in supply chain solutions for the life sciences industry, today announced financial results for the fourth quarter (Q4) and year ended (FY) December 31, 2024. Jerrell Shelton, CEO of Cryoport, commented, "Cryoport ended 2024 with solid resul
NASHVILLE, Tenn., Feb. 18, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) ("Cryoport" or the "Company"), a global leader in supply chain solutions for the life sciences industry, today announced that the Company will report financial results for the fourth quarter and year ended December 31, 2024 on Tuesday, March 4, 2025 after U.S. markets close. In addition to the earnings release, a document titled "Cryoport Fourth Quarter and Full Year 2024 in Review", providing a review of Cryoport's financial and operational performance and a general business update, will be issued at
Q3 2024 Life Sciences Services revenue up 9% year-over-year, including BioStorage/BioServices revenue up 12% year-over-year Supported a record total of 691 global clinical trials as of September 30, 2024Company reaffirmed full year 2024 revenue guidance of $225 to $235 millionNASHVILLE, Tenn., Nov. 7, 2024 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) (Cryoport), a global leader in supply chain solutions for the life sciences industry, today announced financial results for its third quarter (Q3) and first nine months (9M) of 2024. Jerrell Shelton, CEO of Cryoport, remarked, "O
NASHVILLE, Tenn., Oct. 29, 2024 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) ("Cryoport" or the "Company"), a global leader in supply chain solutions for the life sciences industry, today announced that the Company will report financial results for the third quarter ended September 30, 2024 on Thursday, November 7, 2024 after U.S. markets close. In addition to the earnings release, a document titled "Cryoport Third Quarter 2024 in Review", providing a review of Cryoport's financial and operational performance and a general business update, will be issued at 4:05 p.m. ET on Thu
Live Leadership Updates
Cryoport's CRYOGENE will provide Moffitt with state-of-the-art biorepository services TAMPA, Fla. and NASHVILLE, Tenn., Jan. 14, 2025 /PRNewswire/ -- Moffitt Cancer Center, a leading National Cancer Institute-designated comprehensive cancer center, through its wholly owned subsidiary Speros FL, a 775-acre global innovation life sciences campus, and Cryoport, Inc. (NASDAQ:CYRX), a global leader in supply chain solutions for the life sciences industry, today announced a strategic collaboration that will provide CRYOGENE's state-of-the-art biorepository services to Speros in Pasco County, Florida. Cryoport's CRYOGENE business unit is a leading biorepository for the life sciences industry that i
NASHVILLE, Tenn., March 3, 2021 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced its Board of Directors has elected Linda Baddour as a member of the Board, effective March 15, 2021. Linda Baddour is a senior executive with over twenty years of experience in healthcare, life sciences and pharmaceuticals. "Our corporate governance underpins all that we do at Cryoport and we are delighted to strengthen our Board as we leverage our newly expanded global footprint and advanced temperature-controlled supply chain platform to spur our growth," said Jerrell She
BERKELEY, Calif. and VANCOUVER, British Columbia, Dec. 01, 2020 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to announce that Mr. Martin Schmieg has rejoined the Company as a member of its Board of Directors. Having previously served as a member of BriaCell’s Board of Directors from 2016 to 2019, Mr. Schmieg is a “C” level executive with a diversified background in the global biotech, med-tech and pharmaceutical industries with 40 years of business experience. He currently serves as Co-Founder and CEO of ClearIt, L
This live feed shows all institutional transactions in real time.
SC 13G - Cryoport, Inc. (0001124524) (Subject)
SC 13G/A - Cryoport, Inc. (0001124524) (Subject)
SC 13G/A - Cryoport, Inc. (0001124524) (Subject)
SC 13G/A - Cryoport, Inc. (0001124524) (Subject)
SC 13G/A - Cryoport, Inc. (0001124524) (Subject)
SC 13G/A - Cryoport, Inc. (0001124524) (Subject)
SC 13G - Cryoport, Inc. (0001124524) (Subject)
SC 13G/A - Cryoport, Inc. (0001124524) (Subject)
SC 13G/A - Cryoport, Inc. (0001124524) (Subject)
SC 13G - Cryoport, Inc. (0001124524) (Subject)